Emergent BioSolutions Inc. (EBS) is a publicly traded company in the Unknown sector. Across all available filings, 31 corporate insiders have executed 1022 transactions totaling $178.3M, demonstrating a bearish sentiment with -$178.1M in net insider flow. The most recent transaction on Feb 9, 2026 involved a transaction of 918 shares valued at $10.1K.
No significant insider buying has been recorded for EBS in the recent period.
No significant insider selling has been recorded for EBS in the recent period.
Based on recent SEC filings, insider sentiment for EBS is bearish with an Insider Alignment Score of 0/100 and a net flow of -$178.1M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Emergent BioSolutions Inc. (EBS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 31 insiders are actively trading EBS stock, having executed 1022 transactions in the past 90 days. The most active insider is Fuad El-hibri (Executive), who has made 187 transactions totaling $108.8M.
Get notified when executives and directors at EBS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Perl Jessica | SVP, General Counsel, Corp Sec | Payment | 918 | $11.03 | $10.1K | |
| Feb 6, 2026 | S. Lindahl Richard | EVP, Chief Financial Officer | Payment | 5,642 | $10.92 | $61.6K | C-Suite |
| Feb 6, 2026 | S. Lindahl Richard | EVP, Chief Financial Officer | Disposition | 46,155 | $10.92 | $504.0K | C-SuiteLarge |
| Feb 6, 2026 | Hartzel William | SVP, Bioservices | Payment | 630 | $10.92 | $6.9K | |
| Feb 6, 2026 | Hartzel William | SVP, Bioservices | Disposition | 5,771 | $10.92 | $63.0K | |
| Feb 6, 2026 | Anthony Williams Paul | SVP, Products Business | Payment | 1,022 | $10.92 | $11.2K | |
| Feb 6, 2026 | Anthony Williams Paul | SVP, Products Business | Disposition | 8,655 | $10.92 | $94.5K | |
| Feb 6, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Payment | 2,852 | $10.92 | $31.1K | |
| Feb 6, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | Disposition | 28,847 | $10.92 | $315.0K | |
| Dec 14, 2025 | C. Lowry Simon | Executive | Payment | 3,543 | $11.41 | $40.4K | |
| Dec 5, 2025 | Richard Ronald | Executive | Sale | 7,100 | $12.11 | $86.0K | |
| Dec 5, 2025 | Richard Ronald | Executive | Option Exercise | 25,748 | $5.02 | $129.3K | |
| Dec 5, 2025 | Richard Ronald | Executive | Payment | 10,864 | $11.90 | $129.3K | |
| Dec 5, 2025 | Richard Ronald | Executive | Sale | 14,884 | $11.90 | $177.1K | |
| Nov 11, 2025 | Hartzel William | Executive | Payment | 610 | $10.88 | $6.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 326 | $178.2M | 76.9% |
Exercise(M) | 178 | $34.6M | 14.9% |
Payment(F) | 234 | $17.3M | 7.5% |
Disposition(D) | 9 | $987.4K | 0.4% |
Award(A) | 236 | $540.9K | 0.2% |
Purchase(P) | 4 | $139.0K | 0.1% |
Other(J) | 32 | $0 | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Insider selling pressure at Emergent BioSolutions Inc. has increased, with 31 insiders executing 1022 transactions across all time. Total sales of $178.2M significantly outpace purchases of $139.0K, resulting in a net outflow of $178.1M. This selling activity appears largely discretionary, which may warrant closer attention from investors.